Oligonucleotide Therapeutics Society
Recent Articles2026-08-24T06:57:48+00:00
9March, 2022

Support for Ukrainian Scientists

The OTS joins other scientific organizations in seeking to help Ukrainian scientists. Specifically, we invite Ukrainian students, scientists, and industry professionals with interests in the field of nucleic acids and oligonucleotide therapeutics to post their contact information and CVs on the OTS website. We ask our membership to spread ...

28February, 2022

A New ASO Shows Promise in Treating Dravet Syndrome, a Severe Form of Epilepsy

 Typically, a single copy of a gene is enough to support normal growth and development but in a small subset of genes, the loss of one copy can cause serious diseases that are often difficult to treat. One of these conditions, Dravet Syndrome, has no treatment options that directly target ...

9February, 2022

A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS

 Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease in which motor neurons die. Since the motor neurons that die control voluntary muscles, the disease causes great difficulty for those who must live with it. They will experience loss of motor control of the arms and legs which causes them ...

24December, 2021

Looking back… Looking forward

This will be my last contribution that I write as President of our Society. On January 1st, 2022, I will become ‘Immediate Past-President’. David Corey (University of Texas, Southwestern) will take over as President and Richard Geary (Ionis Pharmaceuticals) will become the Society’s next President-Elect. As we delayed this ...

10November, 2021

IKARIA – An Innovative Platform that Yields Long-Acting siRNA

In this year that marks the 20th Anniversary of the discovery of RNA interference as a gene-silencing mechanism in mammalian cells, Alnylam announced another remarkable development in siRNA therapeutics – a platform that could allow for administration of siRNA medications just once a year with highly potent knockdown of ...

28October, 2021

New Miniature CRISPR-Cas Systems Engineered to Function in Human Cells

CRISPR-Cas systems provide a revolutionary approach to curing disease through precise genome editing and CRISPR therapies have delivered promising early successes. However, engineering more highly efficient, compact Cas systems could result in a more versatile tool that could greatly improve and expand CRISPR-based therapeutics. As Dr. Stanley Qi pointed out, ...

26October, 2021

President’s Pick of Presentations from the Annual OTS Meeting

By: Annemieke Aartsma-Rus, Ph.D. The second virtual annual meeting of the Oligonucleotide Therapeutics Society (OTS) took place September 26-29 on a computer or laptop near you. Despite the challenges the pandemic poses on research and development in general, the oligonucleotide therapy field has made many advances, including the first ...

A New ASO Shows Promise in Treating Dravet Syndrome, a Severe Form of Epilepsy

February 28th, 2022|Categories: Perspectives on Current Science|

 Typically, a single copy of a gene is enough to support normal growth and development but in a small subset of genes, the loss of one copy can cause serious ...

Comments Off on A New ASO Shows Promise in Treating Dravet Syndrome, a Severe Form of Epilepsy

A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS

February 9th, 2022|Categories: Perspectives on Current Science|

 Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease in which motor neurons die. Since the motor neurons that die control voluntary muscles, the disease causes great difficulty for those ...

Comments Off on A Potent ASO Shows Encouraging Results in A Single-Patient Pilot Study for ALS

IKARIA – An Innovative Platform that Yields Long-Acting siRNA

November 10th, 2021|Categories: Perspectives on Current Science|

In this year that marks the 20th Anniversary of the discovery of RNA interference as a gene-silencing mechanism in mammalian cells, Alnylam announced another remarkable development in siRNA therapeutics ...

Comments Off on IKARIA – An Innovative Platform that Yields Long-Acting siRNA

New Miniature CRISPR-Cas Systems Engineered to Function in Human Cells

October 28th, 2021|Categories: Perspectives on Current Science|

CRISPR-Cas systems provide a revolutionary approach to curing disease through precise genome editing and CRISPR therapies have delivered promising early successes. However, engineering more highly efficient, compact Cas systems could ...

Comments Off on New Miniature CRISPR-Cas Systems Engineered to Function in Human Cells

President’s Pick of Presentations from the Annual OTS Meeting

October 26th, 2021|Categories: Perspectives on Current Science, Presidents Pick|

By: Annemieke Aartsma-Rus, Ph.D. The second virtual annual meeting of the Oligonucleotide Therapeutics Society (OTS) took place September 26-29 on a computer or laptop near you. Despite the challenges ...

Comments Off on President’s Pick of Presentations from the Annual OTS Meeting

Get the latest news!

  • Category

Go to Top